PomegraMatchpoint Therapeutics closed a $150M Series B on October 7, 2026 to take oral autoimmune drug MPT-062 toward clinical trials in 2027, with no valuation disclosed.
Key Takeaways
- Matchpoint raised a $150M Series B co-led by Nextech Invest and Norwest on October 7, 2026.
- Lead drug MPT-062, an oral T cell modulator, is slated to enter clinical development in 2027.
- Valuation was not disclosed; Sanofi Ventures and Novartis ties anchor the round.
Lead
Matchpoint Therapeutics, a Watertown, Massachusetts biotech building oral covalent small molecules for autoimmune and inflammatory disease, announced a $150M Series B on October 7, 2026. Nextech Invest and Norwest co-led the round. The money is meant to carry the lead asset, MPT-062, to clinical proof-of-concept and to widen the pipeline behind it.
The company has not disclosed a valuation, the molecular target of MPT-062, or its first indication. That leaves a $150M raise for a drug that has not yet dosed a patient and whose mechanism is described only as "T cell modulation."
Who Backed the Round?
Two firms co-led the Series B. Nextech Invest and Norwest led, joined by new investors Invus, BB Biotech, the T1D Fund and BOLD Longevity Growth. Existing backers Access Biotechnology, Atlas Venture, Sanofi Ventures and Digitalis Ventures also participated.
Kanishka Pothula, Managing Partner at Nextech Invest, and Brian Matesic, Principal at Norwest, will join the board. The company's chief executive is Andre Turenne.
The investor list mixes crossover-style generalist money, a public biotech fund in BB Biotech, and a type 1 diabetes philanthropy-backed investor in the T1D Fund. That last name is a hint about where an autoimmune T-cell drug might eventually be tested, though the company has not said so.
How Does This Round Compare With Matchpoint's Earlier Funding?
The Series B is larger than everything Matchpoint raised before it combined in equity terms. The company launched in October 2022 with $100M, made up of a $70M Series A led by Sanofi Ventures and a $30M seed from November 2021 co-led by Atlas Venture and Access Biotechnology.
The step from $70M to $150M in a single round is a 2.1x increase. It arrives four years after the Series A, a long gap for a company that has still not entered the clinic. The company filled part of that gap with non-dilutive money: a July 2025 collaboration with Novartis carried $60M upfront and up to $1B in milestones plus royalties, funding a separate program built on Matchpoint's platform.
Read together, the numbers suggest the Series A did its job at extending runway through discovery and a pharma validation event, and that the Series B is priced on a candidate rather than on a platform promise. Without a disclosed valuation, the step-up in price per share cannot be checked.
What Is MPT-062 and What Does It Do?
MPT-062 is an oral, first-in-class T cell modulator designed to suppress the overactivation of T cells that drives autoimmune and inflammatory disease. Matchpoint expects clinical development to begin in 2027.
The compound comes from the company's covalent chemistry platform, which combines chemical biology, structure-based drug design and computational methods. The pitch is that covalent small molecules can hit biologically validated targets that conventional drugs have not drugged. Matchpoint describes the approach as "precision covalent medicine."
The company's own claim is that MPT-062 could change management of common immune-mediated conditions. That is a statement of ambition, not data, and no preclinical or clinical results have been published.
Why Do Oral Autoimmune Drugs Draw Investor Money?
Oral drugs draw money because most of the current high-value autoimmune market is injectable biologics, and a pill that works through a new mechanism would compete on convenience as well as efficacy. Patients and payers generally prefer tablets to infusions or injections when efficacy is comparable.
The counterargument is safety. Covalent drugs bind permanently to their targets, which can raise off-target and immunogenicity concerns, and drugs that broadly dampen T cells carry infection and malignancy risks that regulators watch closely. Matchpoint has not disclosed a safety package, so investors are underwriting that risk without public evidence.
The 2027 start date also sets a clock. A first-in-human study would likely read out early safety and pharmacology data well after the Series B closes, which means the round funds the period of highest uncertainty for the asset.
What Comes Next for Matchpoint?
The next milestone is regulatory: an IND or equivalent filing and dose initiation for MPT-062 in 2027. Disclosure of the target and lead indication is likely to follow that filing, since the company has so far held both back.
Three scenarios look plausible. A clean early safety profile would support a larger crossover or public financing and could prompt further interest from Sanofi, already an investor, or Novartis, already a partner. A delay in the 2027 start would push cash use into 2028 without a data catalyst. A clinical hold or safety signal would test whether the platform's value rests on one molecule or on the broader pipeline the round also funds.
Outlook
Matchpoint now holds a $150M balance sheet, a pharma partner with up to $1B in milestone potential, and one undisclosed-target drug heading toward first-in-human dosing in 2027. The round says investors will pay for a clinical-stage candidate backed by two pharma relationships, even with mechanism and valuation undisclosed. What it does not yet say is whether covalent T-cell modulation can hold up in patients.